No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
RSLS ReShape Lifesciences
- 0.1653
- -0.0054-3.16%
Close Apr 19 16:00 ET
- 0.1700
- +0.0047+2.84%
Post 19:54 ET
3.88MMarket Cap-86P/E (TTM)
0.1770High0.1652Low79.63KVolume0.1667Open0.1707Pre Close13.44KTurnover0.38%Turnover RatioLossP/E (Static)23.46MShares2.798052wk High0.58P/B3.44MFloat Cap0.141452wk Low--Dividend TTM20.82MShs Float80136000.0000Historical High--Div YieldTTM6.91%Amplitude0.1414Historical Low0.1680Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | ReShape Lifesciences Tweets 'Will #GLP1 Medications Replace #weightloss #surgery? According to ReShape CEO, Paul Hickey, via @InvestingCom, #GLP1s Are a Very Attractive Tool to Fight #obesity. However, Our ReShape Lap-Band Is Safe and Less Invasive'
ReShape Lifesciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Q4 2023 ReShape Lifesciences Inc Earnings Call
ReShape Lifesciences 2023 Rev $8.7M >RSLS
ReShape Lifesciences 2023 Rev $8.7M >RSLS
Express News | ReShape Lifesciences Expects 2024 Operating Expenses To Decrease By More Than 50% Compared to 2023; Reaffirming Commitment To Profitability
Express News | Reshape Lifesciences FY23 Sales $8.678M Miss $8.904M Estimate
Comments
Medical Device Company Secures U.S. Patent For Obesity Treatment
The Future of Obesity Treatment: Breakthroughs and Innovations from ReShape Lifesciences.
In a world where obesity continues to be a pervasive and challenging health issue, innovations in medical technology offer a beacon of hope. Among the leaders in this transformative era is ReShape Lifesciences®, a company dedicated to advancing solutions for weight loss and metabolic health. Recently, the U.S. Patent and Trademark Office (USPTO...
In a world where obesity continues to be a pervasive and challenging health issue, innovations in medical technology offer a beacon of hope. Among the leaders in this transformative era is ReShape Lifesciences®, a company dedicated to advancing solutions for weight loss and metabolic health. Recently, the U.S. Patent and Trademark Office (USPTO...
Update
$ReShape Lifesciences(RSLS.US$ ReShape Lifesciences Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 FLEX
GlobeNewswire· 5 mins ago
GlobeNewswire· 5 mins ago
$ReShape Lifesciences(RSLS.US$ The patent has to come before the product. not after the product. unless you like sharing your profits with other manufacturers.
1
$ReShape Lifesciences(RSLS.US$ Myabe Maxim Group found a strategic M&A partner for them already.
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg